Justia Civil Procedure Opinion Summaries

Dolores Hunter, the personal representative of the estate of Benjamin G. Francis, appealed a series of orders following a jury verdict in a wrongful death, products liability, and fraud action against Philip Morris USA Inc. resulting from Francis’s death from lung cancer. Following the verdict, Hunter moved for a new trial on the basis of evidentiary rulings at trial and on the basis that the verdict was against the weight of the evidence. The superior court initially granted Hunter’s motion for a new trial based on the weight of the evidence but then granted Philip Morris’s motion to reconsider, vacated its first order and denied Hunter’s motion for a new trial. Because the superior court’s orders applied a test that was inconsistent with the “weight of the evidence” new trial standard the Alaska Supreme Court previously established to guide trial courts, the Supreme Court reversed and remanded for reconsideration of Hunter’s motion. View "Hunter v. Philip Morris USA Inc." on Justia Law

After all defendants to the original complaint filed responsive pleadings in Mary Meeks’s medical malpractice suit, Meeks obtained leave of court and filed a first amended complaint, adding as a defendant the manufacturer of a medical device, Hologic, Inc. A doctor performed an outpatient diagnostic hysteroscopy and an endometrial ablation on Meeks at the Northwest Regional Medical Center in Clarksdale using a Novasure medical device manufactured and sold by Hologic to treat Meeks’s menorrhagia. Meeks did not serve the first amended complaint on Hologic but instead filed a second amended complaint without leave of court or permission from all defendants. Hologic filed a motion to dismiss, arguing that Meeks’s claims against Hologic were federally preempted and that Meeks’s claims additionally were barred by the statute of limitations. Because Meeks failed to obtain leave of court or permission from the defendants to file the second complaint, and because the first was never served on Hologic, the Supreme Court found that the statute of limitations had expired against Hologic and that the trial court properly granted Hologic’s motion to dismiss. View "Mary Meeks v. Hologic, Inc." on Justia Law

Deborah Jackson sued Illinois Central Railroad Company under the Federal Employers’ Liability Act (FELA) for the wrongful death of her husband, Charles. Jackson alleged that her husband’s death from lung cancer was caused by his exposure to asbestos while working for the railroad. After the close of discovery, Illinois Central filed a motion for summary judgment and a motion to strike Jackson’s expert, Michael Ellenbecker. Later, Illinois Central moved to strike improper evidence from Jackson’s response to the motion for summary judgment. When Jackson attempted to supplement Ellenbecker’s designation at the summary-judgment hearing, Illinois Central moved ore tenus to strike the supplementation. The Circuit Court denied all of Illinois Central’s motions. Illinois Central appealed. After review, the Mississippi Supreme Court found that Jackson’s expert designation of Ellenbecker was improper summary-judgment evidence because it was not sworn to upon personal knowledge and constituted inadmissible hearsay. Because the supplemental response was unsworn and never was filed, it also was improper. And, because Jackson could not show a genuine issue of material fact without Ellenbecker’s testimony, the Court reversed the denial of summary judgment and rendered judgment in favor of Illinois Central. View "Illinois Central Railroad Company v. Jackson" on Justia Law

Whether a third-party payer (TPP) will cover the cost of a member’s prescription depends on whether that drug is listed in the TPP’s formulary. Pharmacy Benefit Managers prepare TPPs’ formularies of drugs approved for use by TPP members by analyzing research regarding a drug’s cost effectiveness, safety and efficacy. In 1999, the FDA approved Avandia as a prescription for type II diabetes. TPPs included Avandia in their formularies and covered Avandia prescriptions at a favorable rate. GSK downplayed concerns about Avandia’s heart-related side effects. In 2010, the FDA restricted access to Avandia in response to increasing evidence of its cardiovascular risks. TPPs (union health and welfare funds) sued GSK on behalf of themselves and similarly situated TPPs. asserting that GSK’s failure to disclose Avandia’s significant heart-related risks violated the Racketeer Influenced and Corrupt Organizations Act based on predicate acts of mail fraud, wire fraud, tampering with witnesses, and use of interstate facilities to conduct unlawful activity. They also claimed unjust enrichment and violations of the Pennsylvania Unfair Trade Practices and Consumer Protection Law and other states’ consumer protection laws. The Third Circuit affirmed the district court’s finding that the TPPs adequately alleged the elements of standing. View "In Re: Avandia Mktg.,Sales Practices & Prod. Liab." on Justia Law

Plaintiffs were two individuals who purchased Marlboro Light cigarettes in Oregon. Defendant Philip Morris was the company that manufactured, marketed, and sold Marlboro Lights. Plaintiffs brought this action under Oregon’s Unlawful Trade Practices Act (UTPA), alleging that defendant misrepresented that Marlboro Lights would deliver less tar and nicotine than regular Marlboros and that, as a result of that misrepresentation, plaintiffs suffered economic losses. Plaintiffs moved to certify a class consisting of approximately 100,000 individuals who had purchased at least one pack of Marlboro Lights in Oregon over a 30-year period (from 1971 to 2001). The trial court denied plaintiffs’ motion after concluding that individual inquiries so predominated over common ones that a class action was not a superior means to adjudicate the putative class’s UTPA claim. On appeal, a majority of the Court of Appeals disagreed with the trial court’s predominance assessment, concluding that the essential elements of the UTPA claim could be proved through evidence common to the class. The majority remanded to the trial court to reconsider whether, without the trial court’s predominance assessment, a class action was a superior means of litigating the class claims. In granting defendant’s petition for review, the Supreme Court considered whether common issues predominated for purposes of the class action certification decision, and what a private plaintiff in a UTPA case of this nature had to prove. The Supreme Court concluded that the trial court properly denied class certification, and accordingly, it reversed the contrary decision of the Court of Appeals and remanded to the trial court for further proceedings on the individual plaintiffs’ claims. View "Pearson v. Philip Morris, Inc." on Justia Law

This case was a latent-injury silicosis case filed against a Florida corporation that was dissolved. The issue this case presented for the Mississippi Supreme Court's review centered on whether the Florida corporate-survival statute applied to a Mississippi plaintiff, or whether the discovery rule for latent injuries permitted claims to be brought against the foreign corporation after dissolution. Sixteen plaintiffs sued Clark Sand Company, Inc. more than four years after the corporation’s dissolution. The circuit court judge sustained Clark Sand’s motion for summary judgment. "At common law, when a corporation dissolved, it no longer existed, and it could not be sued. But because of the harshness of this rule, Florida, like most states, has adopted a corporate-survival statute that allows plaintiffs to bring suit against a Florida corporation for up to four years after dissolution." Finding no error, the Supreme Court affirmed. View "Williams v. Clark Sand Company, Inc." on Justia Law

Plaintiff Kenneth Badilla bought a pair of work boots at Wal-Mart. He claimed the soles of the boots came unglued, causing him to trip and injure his back. More than three years later, he sued Wal-Mart and its store manager (Defendants) for breach of express and implied warranties. In his complaint plaintiff sought damages for personal injuries he claims were caused by the boots’ alleged failure to conform to their warranties. Defendants moved for summary judgment, which the district court granted on two grounds: (1) that Plaintiff’s complaint was time-barred by the application of the three-year statute of limitation for causes of action for torts; and (2) that there were no genuine issues of material fact to rebut plaintiff’s inability to establish the elements for breach of express and implied warranty. The Court of Appeals affirmed the district court’s grant of summary judgment on the statute of limitations issue, and because its determination on that issue was dispositive, it abstained from addressing the second basis upon which the district court granted summary judgment. Plaintiff sought review of the Court of Appeals’ decision by petition for writ of certiorari, asking this Court to determine whether his claims for personal injury damages resulting from breach of warranties were subject to the four-year limitation period set out in Section 55-2-725 or the three-year limitation period for tort actions found in Section 37-1-8. Upon review, the Supreme Court held that the UCC’s four-year statute of limitation governed breach of warranty claims, including those seeking damages for personal injuries resulting from the breach. View "Badilla v. Wal-Mart Stores East Inc." on Justia Law

Plaintiff, a helicopter pilot, was forced to land a Bell 407 helicopter when the helicopter’s engine suddenly quit working. Plaintiff sued Defendants, alleging that the flameout was caused by false overspeed solenoid activation (FOSSA). Defendants asserted that Plaintiff’s engine flameout was not caused by FOSSA but by Plaintiff’s failure to adequately clear the helicopter of snow and ice before takeoff. The jury returned a defense verdict. After trial, two defendants issued bulletins applicable to the type of engine in Plaintiff’s helicopter addressing FOSSA. Plaintiff filed a motion for a new trial, invoking Fed. R. Civ. P. 60(b)(2) and (3), arguing that the information contained in the bulletins compelled an inference that one or more defendants knew about a “circuit design error” existing at the time of Plaintiff’s accident rendering Bell 407s susceptible to FOSSA but failed to disclose it during discovery or at trial, which failure constituted misconduct. The district court denied Plaintiff’s post-trial motions. The First Circuit vacated in part and remanded, holding that the district judge misconstrued the requirements of the Rule 60(b)(3) burden-shifting inquiry set forth in Anderson v. Cryovac, Inc. Remanded for further proceedings on Plaintiff’s Rule 60(b)(3) motion. View "West v. Bell Helicopter Textron, Inc." on Justia Law

Plaintiffs filed a products liability suit, alleging that defendants are liable for the their injuries after using the medical device known as Infuse. At issue was whether the presence of a so-called “nominal defendant” can prevent the remaining defendants from obtaining a forum non conveniens dismissal when, in the absence of the nominal defendant, the action can and should be pursued in alternative forums. The court concluded that the presence of a nominal defendant cannot defeat a forum non conveniens dismissal which should otherwise be granted. In this case, the trial court correctly granted the forum non conveniens dismissal in favor of all other defendants, but erred in dismissing plaintiffs’ action against the nominal defendant. Instead, the court should have severed the action against the nominal defendant and allowed it to proceed in California. The court affirmed in part and reversed in part. View "David v. Medtronic, Inc." on Justia Law

GE manufactures Omniscan, an FDA-approved gadolinium-based contrast agent that has been associated in some patients with development of nephrogenic systemic fibrosis (NSF), a rare and deadly condition that leads to the hardening (fibrosis) of the kidneys. Omniscan was administered to Wahl for two MRIs she received in Nashville in 2006. About one year later, she displayed the first symptoms of NSF. She was officially diagnosed with NSF in 2010. The Judicial Panel on Multidistrict Litigation consolidated all pre-trial litigation of Omniscan-related cases in the U.S. District Court for the Northern District of Ohio. In 2011, Wahl filed a complaint in that court. With the agreement of Wahl and GE, the MDL judge transferred the case, in 2013, to the Middle District of Tennessee, the “proper venue.” GE then moved for summary judgment, arguing that all Omniscan doses produced from 2004 to 2006 were marked with expiration dates two years after manufacture, so the Omniscan administered to Wahl must have expired no later than 2008; the Tennessee Products Liability Act’s statute of repose requires suits to be instituted within one year of the expiration date appearing on a product’s packaging. The Sixth Circuit affirmed summary judgment, favoring GE, applying Tennessee choice-of-law rules. View "Wahl v. Gen. Elec. Co." on Justia Law